Cart
sales@molnova.com
GSK963 (Racemate)
CAS No. 2049868-46-2
GSK963 (Racemate)( —— )
Catalog No. M20223 CAS No. 2049868-46-2
GSK963 (Racemate) a structurally distinct potent and selective inhibitor of RIP1 kinase(IC50=29 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 39 | Get Quote |
|
| 5MG | 65 | Get Quote |
|
| 10MG | 110 | Get Quote |
|
| 25MG | 222 | Get Quote |
|
| 50MG | 357 | Get Quote |
|
| 100MG | 524 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK963 (Racemate)
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK963 (Racemate) a structurally distinct potent and selective inhibitor of RIP1 kinase(IC50=29 nM).
-
DescriptionGSK963 (Racemate) a structurally distinct potent and selective inhibitor of RIP1 kinase(IC50=29 nM).
-
In Vitro——
-
In VivoAnimal Model:C57BL/6 mice.Dosage:0.2 mg/kg, 2 mg/kg, 10?mg/kg.Administration:IP once.Result:Protected mice from TNF+zVAD-induced hypothermia.
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorRIP1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2049868-46-2
-
Formula Weight230.31
-
Molecular FormulaC14H18N2O?
-
Purity>98% (HPLC)
-
SolubilityDMSO:40 mg/mL (173.67 mM)
-
SMILESCC(C)(C)C(=O)N1N=CCC1c1ccccc1
-
Chemical Name22-Dimethyl-1-(5(S)-phenyl-45-dihydro-pyrazol-1-yl)-propan-1-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Berger SB et al. Characterization of GSK'963: a structurally distinct potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.
molnova catalog
related products
-
Necrostatin-1
Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.
-
GSK3145095
GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
-
Bioymifi
Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis
